HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J launches online campaign

This article was originally published in The Rose Sheet

Executive Summary

Johnson & Johnson launches new online campaign and microsite 1http://www.JohnsonsForYou.com\Escape, announced April 9. Site is designed to promote Johnson's award-winning skin-care line Melt Away Stress and features a Jamaica getaway sweepstakes, user-generated "Express Your Stress" contest, and celebrity quotes including video in which actress Anna Ortiz of ABC's Ugly Betty appears. Campaign "targets young women in hopes of bringing them fun and engaging information to better help them escape from their stress and achieve beautiful, soft skin," press release notes. J&J has partnered with Glam Media - "no. 1 in reach for women online," with a network of over 450 Web publishers - in effort to distribute and promote site's content. New York-based interactive marketing agency Deep Focus was tapped to develop campaign's creative content and applications...

You may also be interested in...



Lilly Taps Loxo Execs To Bring Back That Biotech Feeling

Almost a year after acquiring Loxo Oncology, Lilly is combining its Lilly Research Laboratories staff with a group headed by three top Loxo execs to lead cancer R&D and business development.

Tech Companies Grappling With A Brave New World Of Regulations While Developing Digital-Health Products

Software firms interested in the digital-health arena are engaging US FDA more and bolstering their regulatory credentials to navigate an unfamiliar regulatory landscape, industry experts tell Medtech Insight.

Biosimilars: US FDA Considering ‘Guardrails’ To Prevent Misinformation

Agency wants to ensure patients ‘aren’t unnecessarily or unfairly scared off or intimidated’ from taking biosimilars, Office of Therapeutic Biologics and Biosimilars' acting policy director Eva Temkin tells the FDA/CMS Summit; Temkin says recent guidance on biosimilar insulins shows agency is trying to be flexible on interchangeability data requirements.


UsernamePublicRestriction

Register

RS015373

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel